<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301951</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000465362</org_study_id>
    <secondary_id>UCSF-04253</secondary_id>
    <secondary_id>UCSF-2407</secondary_id>
    <secondary_id>UCSF-H24045-25271-02</secondary_id>
    <nct_id>NCT00301951</nct_id>
  </id_info>
  <brief_title>Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer</brief_title>
  <official_title>Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both&#xD;
      the growth of cancer cells and the patient's immune system from rejecting the donor's stem&#xD;
      cells. When the healthy stem cells from a donor are infused into the patient, they may help&#xD;
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.&#xD;
      Sometimes the transplanted cells from a donor can make an immune response against the body's&#xD;
      normal cells. Giving chemotherapy, such as fludarabine and busulfan, and antithymocyte&#xD;
      globulin before transplant and tacrolimus and mycophenolate mofetil after transplant may stop&#xD;
      this from happening.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving low-dose fludarabine and busulfan&#xD;
      together with anti-thymocyte globulin, followed by donor umbilical cord blood transplant&#xD;
      works in treating patients with advanced hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the feasibility of performing umbilical cord blood transplants in older patients&#xD;
           or younger infirm patients with advanced hematologic malignancies using a&#xD;
           reduced-intensity preparative regimen, as determined by &gt; 80% engraftment rate at day&#xD;
           180 and a &lt; 50% transplant-related mortality rate at day 100.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Describe the time to neutrophil and platelet recovery in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine disease-specific, event-free, and overall survival rate at days 180 and 360.&#xD;
&#xD;
        -  Determine the incidence, severity, and timing of acute and chronic graft-versus-host&#xD;
           disease in patients treated with this regimen.&#xD;
&#xD;
        -  Evaluate T-cell, B-cell, and natural killer cell recovery in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Assess lineage-specific chimerism after transplantation and describe the contribution of&#xD;
           each individual cord blood unit to post-transplantation hematopoiesis.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Reduced-intensity preparative regimen: Patients receive fludarabine IV over 30 minutes&#xD;
           on days -8 to -4, busulfan IV over 2 hours 4 times daily on days -4 and -3, and&#xD;
           anti-thymocyte globulin IV over 6 hours on days -3 to -1.&#xD;
&#xD;
        -  Allogeneic umbilical cord blood transplantation: Patients undergo allogeneic umbilical&#xD;
           cord blood transplant on day 0. Patients receive sargramostim (GM-CSF) subcutaneously or&#xD;
           IV beginning on day 7 and continuing until blood counts recover.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive tacrolimus IV&#xD;
           continuously over 24 hours or orally (as tolerated) beginning on day -2 and continuing&#xD;
           for approximately 9 months. Patients also receive oral mycophenolate mofetil twice daily&#xD;
           on days 1-50.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Feasibility of donor cord blood transplant</measure>
    <time_frame>up to 36 months post transplant</time_frame>
    <description>as determined by &gt; 80% engraftment rate at day 180 and a &lt; 50% transplant-related mortality rate at day 100</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>cord blood transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following advanced hematologic malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) meeting the following criteria:&#xD;
&#xD;
                    -  Considered incurable with chemotherapy&#xD;
&#xD;
                    -  Marrow blasts ≤ 10% (may be achieved using standard chemotherapy regimen)&#xD;
&#xD;
                    -  Meets any of the following criteria:&#xD;
&#xD;
                         -  High-risk cytogenetics (-7, -7q, -5, -5q, t(6,9), t(9,11), complex [≥ 3&#xD;
                            abnormalities], Philadelphia chromosome positive [Ph+])&#xD;
&#xD;
                         -  AML evolved from prior myelodysplasia&#xD;
&#xD;
                         -  AML secondary to prior chemotherapy&#xD;
&#xD;
                         -  Failed to achieve remission&#xD;
&#xD;
                         -  In second or subsequent remission&#xD;
&#xD;
                         -  Refractory relapse&#xD;
&#xD;
               -  Myelodysplastic syndromes (MDS) meeting the following criteria:&#xD;
&#xD;
                    -  Must have high-risk features, including any of the following:&#xD;
&#xD;
                         -  Intermediate-2 or high risk International Prognostic Scoring System&#xD;
                            (IPSS) score&#xD;
&#xD;
                         -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  Marrow blasts ≤ 20% (chemotherapy may be given to achieve target blast&#xD;
                       levels)&#xD;
&#xD;
                    -  No rapidly progressive disease&#xD;
&#xD;
               -  Acute lymphoblastic leukemia meeting the following criteria:&#xD;
&#xD;
                    -  Considered incurable with chemotherapy&#xD;
&#xD;
                    -  Meets any of the following criteria:&#xD;
&#xD;
                         -  High-risk cytogenetics (Ph+, t(4,11), 11q23 abnormalities, or monosomy&#xD;
                            7)&#xD;
&#xD;
                         -  Required &gt; 1 induction course to achieve remission&#xD;
&#xD;
                         -  Failed to enter remission&#xD;
&#xD;
                         -  In second or subsequent remission&#xD;
&#xD;
                    -  Marrow blasts ≤ 10% (chemotherapy may be given to achieve target blast&#xD;
                       levels)&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Chronic phase CML that failed imatinib mesylate therapy, as defined by&#xD;
                       progressive disease or failed to achieve a major cytogenetic response at 1&#xD;
                       year after initiation of therapy&#xD;
&#xD;
                    -  Accelerated phase CML meeting 1 of the following criteria:&#xD;
&#xD;
                         -  Failed to achieve a complete cytogenetic remission at 1 year after&#xD;
                            initiation of therapy&#xD;
&#xD;
                         -  Failed to achieve any cytogenetic response after 6 months of therapy&#xD;
&#xD;
                         -  Progressive disease, as demonstrated by worsening cytogenetic response&#xD;
                            in 2 consecutive analyses separated by 4 weeks&#xD;
&#xD;
                    -  In blast crisis with &lt; 10% blasts in bone marrow&#xD;
&#xD;
               -  Multiple myeloma meeting the following criteria:&#xD;
&#xD;
                    -  Stage I-III disease&#xD;
&#xD;
                    -  Meets any of the following criteria:&#xD;
&#xD;
                         -  In relapse after autologous transplantation&#xD;
&#xD;
                         -  Refractory to ≥ 2 prior conventional myeloma therapies&#xD;
&#xD;
                         -  Chromosome 13 abnormalities (may be enrolled at diagnosis or after&#xD;
                            initial progression)&#xD;
&#xD;
               -  Lymphoma&#xD;
&#xD;
                    -  The following subtypes are eligible:&#xD;
&#xD;
                         -  Diffuse large cell&#xD;
&#xD;
                         -  Follicular large cell&#xD;
&#xD;
                         -  Mantle cell&#xD;
&#xD;
                         -  Peripheral T-cell&#xD;
&#xD;
                         -  T-natural killer (T-NK) cell&#xD;
&#xD;
                         -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  Must have progressed, recurred after prior therapy, or failed to respond to&#xD;
                       primary therapy&#xD;
&#xD;
                    -  Relapsed disease after autologous stem cell transplantation (SCT) allowed&#xD;
&#xD;
               -  Low-grade non-Hodgkin's lymphoma meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Relapsed or refractory disease after ≥ 2 chemotherapy-based treatment&#xD;
                       regimens&#xD;
&#xD;
                    -  Relapsed after autologous SCT&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Relapsed or refractory disease after ≥ 2 chemotherapy-based treatment&#xD;
                       regimens&#xD;
&#xD;
                    -  Relapsed after autologous SCT&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Age 55-70 years&#xD;
&#xD;
               -  Under age 55 and deemed ineligible for conventional high-dose chemotherapy, as&#xD;
                  indicated by any of the following:&#xD;
&#xD;
                    -  Poor cardiac function (i.e., LVEF &lt; 40%)&#xD;
&#xD;
                    -  Poor pulmonary function (i.e., DLCO &lt; 50%)&#xD;
&#xD;
                    -  Hepatic dysfunction&#xD;
&#xD;
                    -  Prior myeloablative therapy&#xD;
&#xD;
          -  Not eligible for autologous SCT or conventional therapy&#xD;
&#xD;
          -  Umbilical cord blood donor available&#xD;
&#xD;
               -  Matched at ≥ 4 of 6 HLA antigens (A, B, and DR)&#xD;
&#xD;
               -  Has 1-3 units of umbilical cord blood available&#xD;
&#xD;
               -  Must not have an HLA-identical or 1 antigen mismatched related donor or potential&#xD;
                  HLA-matched unrelated donor readily available NOTE: A new classification scheme&#xD;
                  for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of&#xD;
                  &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
                  &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
                  terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  AST and alkaline phosphatase &lt; 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Hepatitis C or active hepatitis B virus (HBV) allowed if ≤ grade 2 fibrosis and/or&#xD;
             inflammation by liver biopsy&#xD;
&#xD;
               -  Patients with history of HBV infection should be tested for hepatitis B epsilon&#xD;
                  (HBe) antigen, anti-HBe, and HBV DNA (quantitative)&#xD;
&#xD;
               -  Patients with active HBV viral replication should receive antiviral therapy&#xD;
&#xD;
          -  Ejection fraction &gt; 30%&#xD;
&#xD;
          -  DLCO ≥ 40%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection requiring ongoing antibiotic treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas G. Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 9, 2006</study_first_submitted>
  <study_first_submitted_qc>March 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

